DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1948)

Multiple Myeloma | Current Treatment | Detailed, Expanded Analysis (US)

Multiple Myeloma | Current Treatment | Detailed, Expanded Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The treatment of multiple myeloma has advanced considerably in recent years with Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remaining  key cornerstones of treatment. Janssen’s targeting antibody, Darzalex, has gained numerous label expansions and experienced rapid uptake since its initial 2015 approval. Amgen’s Kyprolis and Takeda’s Ninlaro are both approved for relapsed/refractory (R/R) multiple myeloma, and both have generated considerable physician interest. The plethora of regimens used to treat multiple myeloma poses decision-making challenges both in the clinic and in drug development.

Questions Answered 

  • What uptake have Darzalex-based and Pomalyst-based regimens experienced in the treatment of R/R symptomatic multiple myeloma, according to surveyed hematologist-oncologists?
  • What is the patient share of key therapies and regimens used to treat newly diagnosed and R/R multiple myeloma?
  • How do drug-treatment rates vary between key multiple myeloma patient segments according to stage of disease and line of therapy?
  • What drivers and obstacles influence treatment decisions in the newly diagnosed symptomatic multiple myeloma setting for select key regimens?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered:  United States.

Primary research: Survey of 102 hematologist-oncologists in the United States fielded in January 2019.

Key drugs covered: Revlimid, Pomalyst, Velcade, Kyprolis, Darzalex, Empliciti, Ninlaro, Farydak.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Current Treatment Physician Insights Multiple Myeloma US [May 2019]

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Dwaipayan Chatterjee, M.Pharm
  • Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group. He holds a degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.

Purchase Report

Recent reports:
You may also be interested in: